#STOK↓

STOK/ 02/05/2026 · 8:56 AM

Guggenheim Starts Coverage on Stoke Therapeutics with Buy Rating and $60 Target

Guggenheim initiates coverage on Stoke Therapeutics, highlighting Zorevunersen’s potential as a disease-modifying treatment for Dravet syndrome and projecting $2.5B peak sales.

STOK/ 01/11/2026 · 5:39 PM

FDA Requests Additional Data on Stoke's Dravet Syndrome Treatment

Stoke Therapeutics continues discussions with FDA for expedited approval of zorevunersen for Dravet syndrome after regulators request more information on the epilepsy treatment.